AI Expands into Pharmaceutical Manufacturing Operations

GlobalData's monthly "Bio/Pharmaceutical Outsourcing" report, distributed via InvestorIdeas, states that AI is expanding from drug discovery into pharmaceutical manufacturing. Digital twins, predictive maintenance, and real-time quality monitoring are being applied to cut downtime, reduce waste, and improve batch consistency. The report notes these tools allow manufacturers to identify and test production changes in virtual environments before live deployment.

The capability remains emerging rather than established. Many companies are still running pilot programs rather than routine production deployments. Edita Hamzic, Healthcare Analyst at GlobalData, is quoted as saying: "While many pharmaceutical companies are investing in AI, implementation remains the biggest challenge. Many companies face problems with outdated systems, uneven data quality, and difficulties in moving from pilot projects to routine use in highly regulated environments. Success will therefore depend on execution and the ability to combine manufacturing expertise with digital infrastructure in day-to-day manufacturing operations. Companies that see AI as part of their operational model, not as a standalone technology project, are most likely to benefit."

FDA and EMA are beginning to integrate AI into manufacturing oversight with differing priorities. Per the report, the FDA is already using AI to determine which facilities are selected for its new one-day inspection pilot, directing inspectors toward higher-risk sites - though the selection criteria remain opaque. The EMA is more focused on safeguards, supporting AI use across the medicine lifecycle only where it is used transparently and in a human-centered way.

Pharmaceutical manufacturing faces pressure to meet growing demand in high-value therapy areas including obesity and diabetes treatments. The report frames the primary AI opportunity as improving performance of existing facilities rather than building new capacity.

"Rather than replacing established manufacturing practices, AI is being harnessed to strengthen them. AI is therefore becoming increasingly important in drug manufacturing as the sector moves towards systems that link production, quality, and regulation more closely than before."

Industry-pattern observations: digital twins enable virtual testing of process changes before live deployment, and predictive maintenance uses sensor telemetry and anomaly detection to reduce unplanned downtime. These approaches require reliable time-series data, consistent metadata, and integration across process control systems and quality databases. Common barriers in similar factory-floor AI pilots include data siloes, variable sensor coverage, and legacy control systems that limit real-time analytics.